Bristol Myers Squibb (BMY) slides as shares trade ex-dividend, with investors also weighing near-term portfolio transition risks

Bristol Myers Squibb (BMY) is down 3.3% today. Here is some analysis on what might have caused this price movement.

Analysis: A key mechanical driver appears to be the stock trading around its ex-dividend/record-date window, which can pressure the share price as the dividend value comes out of the stock. The move may also reflect incremental caution about the company’s medium-term revenue transition, including the approaching loss of European exclusivity for Eliquis, which has been a major earnings contributor.

Details:

Bristol Myers Squibb declared a $0.63 quarterly dividend payable May 1, 2026, to shareholders of record as of April 2, 2026, putting the stock in an ex-dividend/record-date period that often leads to a downward price adjustment.

Market data calendars list April 2, 2026 as the upcoming ex-dividend date for the $0.63 payout, reinforcing the likelihood of a dividend-related technical pullback.

Separately, investors have been focused on the expected loss of European market exclusivity for Eliquis on May 19, 2026, an event that external industry forecasts tie to a meaningful step-down in sales in that region.

This could also be simple mean reversion after prior strength tied to earlier company guidance and dividend-related attention, with no single new headline dominating the tape.

Sources:

Bristol Myers Squibb Investor Relations, Stock Analysis, Yahoo Finance

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$BMY Hedge Fund Activity

We have seen 1,092 institutional investors add shares of $BMY stock to their portfolio, and 1,086 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 65,718,198 shares (-75.4%) from their portfolio in Q4 2025, for an estimated $3,544,839,600
AQR CAPITAL MANAGEMENT LLC added 16,332,924 shares (+172.6%) to their portfolio in Q4 2025, for an estimated $880,997,920
CAPITAL INTERNATIONAL INVESTORS removed 11,395,497 shares (-35.2%) from their portfolio in Q4 2025, for an estimated $614,673,108
JPMORGAN CHASE & CO removed 10,813,011 shares (-12.5%) from their portfolio in Q4 2025, for an estimated $583,253,813
WELLINGTON MANAGEMENT GROUP LLP removed 10,234,541 shares (-59.7%) from their portfolio in Q4 2025, for an estimated $552,051,141
MARSHALL WACE, LLP added 9,310,682 shares (+607.1%) to their portfolio in Q4 2025, for an estimated $502,218,187
PACER ADVISORS, INC. removed 9,304,698 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $501,895,410

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$BMY Government Contracts

We have seen $8,350,465 of award payments to $BMY over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

REVLIMID, POMALYST, CAMZYOS SPECIALTY PHARMACEUTICALS: $848,445
EMERGENCY BREYANZI INFUSION: $670,085
ABECMA FOR CAR-T: $338,932
ABECMA CAR T FOR TRANSPLANT: $338,932

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.

$BMY Congressional Stock Trading

Members of Congress have traded $BMY stock 5 times in the past 6 months. Of those trades, 2 have been purchases and 3 have been sales.

Here’s a breakdown of recent trading of $BMY stock by members of Congress over the last 6 months:

REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 3 times. They made 2 purchases worth up to $30,000 on 12/19, 11/12 and 1 sale worth up to $15,000 on 10/09.
REPRESENTATIVE JULIE JOHNSON has traded it 2 times. They made 0 purchases and 2 sales worth up to $30,000 on 12/18, 11/13.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

$BMY Analyst Ratings

Wall Street analysts have issued reports on $BMY in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Piper Sandler issued a "Overweight" rating on 02/23/2026
B of A Securities issued a "Buy" rating on 12/15/2025
Guggenheim issued a "Buy" rating on 12/12/2025

To track analyst ratings and price targets for $BMY, check out Quiver Quantitative's $BMY forecast page.

$BMY Price Targets

Multiple analysts have issued price targets for $BMY recently. We have seen 14 analysts offer price targets for $BMY in the last 6 months, with a median target of $60.0.

Here are some recent targets:

Rajesh Kumar from HSBC set a target price of $60.0 on 03/17/2026
Trung Huynh from RBC Capital set a target price of $60.0 on 02/25/2026
David Amsellem from Piper Sandler set a target price of $75.0 on 02/23/2026
Emily Field from Barclays set a target price of $75.0 on 02/20/2026
Mohit Bansal from Wells Fargo set a target price of $60.0 on 02/06/2026
Seamus Fernandez from Guggenheim set a target price of $72.0 on 02/06/2026
Geoff Meacham from Citigroup set a target price of $64.0 on 02/06/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.